Lymphocyte Changes in Renal Cell Carcinoma Patients Treated with rIL-2
Author Information
Author(s): R.A.J. Janssen, D.Th. Sleijfer, A.A. Heijnl, N.H. Mulder, T.H. The, L. de Leijl
Primary Institution: University Hospital Groningen
Hypothesis
The activation status of peripheral blood lymphocytes before therapy correlates with the response to subcutaneously applied rIL-2 therapy in renal cell carcinoma patients.
Conclusion
The study shows that higher numbers of activated lymphocytes before therapy are associated with better treatment outcomes.
Supporting Evidence
- Patients with complete remission had significantly higher lymphocyte counts before treatment.
- Subcutaneous rIL-2 therapy resulted in changes in lymphocyte composition similar to intravenous administration.
- High numbers of CD8bright and CD56 positive cells expressing HLA-Dr were found in patients with better outcomes.
Takeaway
Doctors looked at blood cells from cancer patients before and after treatment to see if the cells could predict how well the treatment would work.
Methodology
Patients received subcutaneous rIL-2 therapy, and their lymphocyte phenotypes were analyzed using flow cytometry before and after treatment.
Limitations
The study only included a small number of patients and did not establish a direct correlation between lymphocyte changes and treatment response.
Participant Demographics
16 male and 11 female patients with an average age of 59 years.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website